Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

Ann Transl Med. 2015 Jan;3(1):7. doi: 10.3978/j.issn.2305-5839.2014.10.06.


Malignant gliomas, such as glioblastoma multiforme (GBM), present some of the greatest challenges in the management of cancer patients worldwide. Even with aggressive surgical resections and recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal and quality of life is poor. Although new molecular pathways crucial to the biology and invasive ability of GBM are coming to light, translation of basic science achievements into clinical practice is slow. Optimal management requires a multidisciplinary approach and knowledge of potential complications arising from both disease and treatment. To help illustrate "where we are going" with GBM, we here include a detailed depiction of the molecular alterations underlying this fatal disease, as well as intensive research over the past two decades that has led to considerable advances in the understanding of basic GBM biology, pathogenesis and therapeutic approaches.

Keywords: Glioblastoma; targeted therapies; temozolomide (TMZ).

Publication types

  • Review